Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: A preliminary study
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.45, pp.144-149, 2013 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 45
- Publication Date: 2013
- Doi Number: 10.1016/j.pnpbp.2013.04.020
- Journal Name: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.144-149
- Keywords: Antioxidant, Deficit schizophrenia, Oxidative stress, PLACEBO-CONTROLLED TRIAL, LIPID-PEROXIDATION, SUPEROXIDE-DISMUTASE, GINKGO-BILOBA, ENZYME LEVELS, DEFENSE SYSTEM, FATTY-ACIDS, VITAMIN-E, HALOPERIDOL, BRAIN
- Akdeniz University Affiliated: No
Abstract
Introduction: Deficit schizophrenia (DS) is defined for identifying a relatively homogeneous subgroup of patients with diagnosis of schizophrenia, characterized by the presence of primary and enduring negative symptoms. There have been several studies which investigated the status of oxidative stress and total antioxidant level in patients with schizophrenia. However, there is not any study which researched differences between DS and nondeficit schizophrenia (NDS) in terms of status of oxidative stress and antioxidant level. We hypothesized that patients with DS would have different status of oxidative stress and antioxidant levels compared with patients with NDS.